MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
11.47
-0.53
-4.42%
After Hours: 11.47 0 0.00% 16:30 12/16 EST
OPEN
11.92
PREV CLOSE
12.00
HIGH
12.10
LOW
11.04
VOLUME
65.05K
TURNOVER
--
52 WEEK HIGH
46.80
52 WEEK LOW
3.760
MARKET CAP
70.58M
P/E (TTM)
-0.9029
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALGS last week (1208-1212)?
Weekly Report · 1d ago
Aligos Therapeutics Grants Stock Options to New Hires Under 2024 Inducement Plan
Reuters · 4d ago
ALIGOS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
TipRanks · 4d ago
Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
TipRanks · 5d ago
Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART
TipRanks · 5d ago
Aligos Therapeutics Announces Data From Four Presentations, Including Two Oral Presentations, At HEP-DART 2025 Meeting
Benzinga · 5d ago
Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B
Reuters · 5d ago
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Webull offers Aligos Therapeutics Inc stock information, including NASDAQ: ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.